Clinical Trial Update: Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis [Phase 3]

View source ↗

Summary

This update reports results from an open-label extension study of upadacitinib in adults with moderate-to-severe atopic dermatitis, with the Phase 3 trial now c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2025-01-09